Patents Assigned to Probiodrug
-
Patent number: 10603367Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.Type: GrantFiled: January 10, 2018Date of Patent: March 31, 2020Assignee: Probiodrug AGInventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
-
Patent number: 9676843Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: September 3, 2015Date of Patent: June 13, 2017Assignee: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Patent number: 9657089Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: May 19, 2014Date of Patent: May 23, 2017Assignee: PROBIODRUG AGInventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
-
Patent number: 9656991Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: GrantFiled: April 18, 2008Date of Patent: May 23, 2017Assignee: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, André J. Niestroj, Robert Sommer
-
Patent number: 9650362Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.Type: GrantFiled: September 23, 2015Date of Patent: May 16, 2017Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
-
Patent number: 9610368Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.Type: GrantFiled: December 15, 2014Date of Patent: April 4, 2017Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
-
Patent number: 9512115Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.Type: GrantFiled: March 14, 2014Date of Patent: December 6, 2016Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Mirko Buchholz, Robert Sommer, Antje Meyer, Hans-Ulrich Demuth
-
Patent number: 9512082Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: GrantFiled: April 18, 2008Date of Patent: December 6, 2016Assignee: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, André J. Niestroj
-
Patent number: 9462793Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: GrantFiled: January 14, 2009Date of Patent: October 11, 2016Assignee: PROBIODRUG AGInventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
-
Patent number: 9277737Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.Type: GrantFiled: May 6, 2013Date of Patent: March 8, 2016Assignee: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
-
Patent number: 9181233Abstract: The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.Type: GrantFiled: March 3, 2011Date of Patent: November 10, 2015Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Daniel Ramsbeck, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
-
Patent number: 9173885Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.Type: GrantFiled: June 5, 2013Date of Patent: November 3, 2015Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
-
Patent number: 9157918Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).Type: GrantFiled: July 23, 2013Date of Patent: October 13, 2015Assignee: PROBIODRUG AGInventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer
-
Patent number: 9156907Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular, Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: October 4, 2011Date of Patent: October 13, 2015Assignee: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Patent number: 9126987Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, wherein R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R2 represents alkyl; carbocyclyl which may optionally be substituted by alkyl; alkenyl; alkynyl, provided a triple bond is not adjacent to X; -alkyl-aryl; -alkyl-heteroaryl; -alkyl-heterocyclyl in which heterocyclyl may optionally be substituted by alkyl; -alkyl-carbocyclyl in which carbocyclyl may optionally be substituted by alkyl; aryl; heteroaryl; or H; X represents S or NR3; R3 represents H or C1-4 alkyl.Type: GrantFiled: November 28, 2007Date of Patent: September 8, 2015Assignee: PROBIODRUG AGInventors: Ulrich Heiser, Daniel Ramsbeck, Mirko Buchholz, Andre J. Niestroj
-
Patent number: 9034907Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R1 represents and R2, R3, R4, R5, R6, X1, X2, X3, X4, Y and Z are as defined throughout the description and the claims.Type: GrantFiled: April 18, 2008Date of Patent: May 19, 2015Assignee: Probiodrug AGInventors: Mirko Buchholz, Ulrich Heiser
-
Patent number: 8962860Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, X and Y are as defined herein are inhibitors of glutaminyl cyclase and are therefore useful in treating conditions that can be treated by modulation of glutaminyl cyclase activity.Type: GrantFiled: September 4, 2009Date of Patent: February 24, 2015Assignee: Probiodrug AGInventors: Ulrich Heiser, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Almstetter, Michael Thormann, Andreas Treml, Hans-Ulrich Demuth, Torsten Hoffman
-
Patent number: 8945510Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.Type: GrantFiled: May 24, 2012Date of Patent: February 3, 2015Assignee: Probiodrug AGInventors: Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
-
Patent number: 8889709Abstract: The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.Type: GrantFiled: September 4, 2009Date of Patent: November 18, 2014Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Michael Wermann, Holger Cynis, Astrid Kehlen, Daniel Friedrich, Torsten Hoffmann, Kathrin Gans, Jens-Ulrich Rahfeld, Ulrich Heiser, Michael Almstetter, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Thormann, Andreas Treml
-
Patent number: 8859250Abstract: Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.Type: GrantFiled: February 26, 2013Date of Patent: October 14, 2014Assignee: Probiodrug AGInventors: Stephan Schilling, Jens-Ulrich Rahfeld, Birgit Koch, Michael Wermann, Christoph Parthier, David Ruiz-Carillo, Milton T. Stubbs